Imfinzi

News

AstraZeneca's Imfinzi fails in cervical cancer bid

AstraZeneca's hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for wo

News

AZ's Imfinzi is first immunotherapy to raise survival in bil...

AstraZeneca's checkpoint inhibitor Imfinzi has become the first cancer immunotherapy to improve survival in previously-untreated patients with biliary tract cancer (BTC), a rare and aggress

News

AZ's COVID-19 jab sales top $1.2bn, but come at a loss

AstraZeneca said this morning that it has made $1.2 billion in sales from its COVID-19 vaccine Vaxzevria in the first half of this year, but making it available at no profit had weighed on

News

AstraZeneca bags Imfinzi okay in big Chinese lung cancer mar...

China has approved AstraZeneca's PD-1/PD-L1 inhibitor Imfinzi to treat small-cell lung cancer (SCLC), an aggressive form of the disease that accounts for around 15% of all lung cancer cases

News

AZ withdraws Imfinzi in US bladder cancer use after trial fa...

AstraZeneca has suffered a setback after it voluntarily withdrew its cancer immunotherapy Imfinzi (durvalumab) in a bladder cancer indication in the US.

News

AZ nabs a positive study for Imfinzi plus tremelimumab in li...

After a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi plus tremelimumab in advanced liver cancer.

AstraZeneca's Imfinzi fails in cervical cancer bid

AZ's Imfinzi is first immunotherapy to raise survival in bil...

AZ's COVID-19 jab sales top $1.2bn, but come at a loss

AstraZeneca bags Imfinzi okay in big Chinese lung cancer mar...

AZ withdraws Imfinzi in US bladder cancer use after trial fa...

AZ nabs a positive study for Imfinzi plus tremelimumab in li...

Setback for MSD as German court blocks Keytruda SC launch

How to meet your physicians where they are online

Imfinzi

Editor's Picks